One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
08 2021
Historique:
received: 19 01 2021
accepted: 10 03 2021
revised: 09 03 2021
pubmed: 21 4 2021
medline: 14 9 2021
entrez: 20 4 2021
Statut: ppublish

Résumé

To assess olipudase alfa enzyme replacement therapy for non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in children. This phase 1/2, international, multicenter, open-label trial (ASCEND-Peds/NCT02292654) administered intravenous olipudase alfa every 2 weeks with intrapatient dose escalation to 3 mg/kg. Primary outcome was safety through week 64. Secondary outcomes included pharmacokinetics, spleen and liver volumes, lung diffusing capacity (DL Twenty patients were enrolled: four adolescents (12-17 years), nine children (6-11 years), and seven infants/early child (1-5 years). Most adverse events were mild or moderate, including infusion-associated reactions (primarily urticaria, pyrexia, and/or vomiting) in 11 patients. Three patients had serious treatment-related events: one with transient asymptomatic alanine aminotransferase increases, another with urticaria and rash (antidrug antibody positive [ADA+]), and a third with an anaphylactic reaction (ADA+) who underwent desensitization and reached the 3 mg/kg maintenance dose. Mean splenomegaly and hepatomegaly improved by >40% (p < 0.0001). Mean % predicted DL In this study in children with chronic ASMD, olipudase alfa was generally well-tolerated with significant, comprehensive improvements in disease pathology across a range of clinically relevant endpoints.

Identifiants

pubmed: 33875845
doi: 10.1038/s41436-021-01156-3
pii: S1098-3600(21)05062-0
pmc: PMC8354848
doi:

Substances chimiques

Recombinant Proteins 0
Sphingomyelin Phosphodiesterase EC 3.1.4.12
olipudase alfa EC 3.1.4.12

Banques de données

ClinicalTrials.gov
['NCT02292654']

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1543-1550

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. The Author(s).

Références

Nature. 2014 Jun 5;510(7503):58-67
pubmed: 24899305
J Pediatr. 2003 Apr;142(4):424-8
pubmed: 12712061
J Pediatr. 2006 Oct;149(4):554-9
pubmed: 17011332
Annu Rev Biochem. 2019 Jun 20;88:461-485
pubmed: 31220974
Mol Genet Metab. 2016 Jul;118(3):206-213
pubmed: 27198631
Rev Mal Respir. 2017 Oct;34(8):900-968
pubmed: 28939155
Mol Genet Metab. 2015 Feb;114(2):217-25
pubmed: 25092414
Radiology. 2006 Jan;238(1):339-45
pubmed: 16304086
Mol Genet Metab. 2015 Sep-Oct;116(1-2):88-97
pubmed: 26049896
Mol Genet Metab. 2017 Jan - Feb;120(1-2):27-33
pubmed: 28164782
Pediatrics. 2004 Dec;114(6):e672-7
pubmed: 15545621
Mol Genet Metab. 2019 Feb;126(2):98-105
pubmed: 30514648
Pediatrics. 2008 Aug;122(2):e341-9
pubmed: 18625664
J Rheumatol. 2015 Nov;42(11):2168-71
pubmed: 25729034
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):145-57
pubmed: 25987169
Genet Med. 2013 Aug;15(8):618-23
pubmed: 23412609
Mol Genet Metab. 2014 Feb;111(2):209-11
pubmed: 24418695
J Pediatr. 2004 Jul;145(1):77-81
pubmed: 15238911
Semin Hematol. 2004 Oct;41(4 Suppl 5):4-14
pubmed: 15468045
Orphanet J Rare Dis. 2017 Feb 23;12(1):41
pubmed: 28228103
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
J Pediatr Gastroenterol Nutr. 1991 Jul;13(1):104-9
pubmed: 1919942
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Genet Med. 2016 Jan;18(1):34-40
pubmed: 25834946
Lung. 2016 Aug;194(4):511-8
pubmed: 27164983
Am Rev Respir Dis. 1981 Feb;123(2):185-9
pubmed: 7235357
Am J Med Genet A. 2012 Nov;158A(11):2835-42
pubmed: 22991292
AAPS J. 2017 Nov;19(6):1576-1586
pubmed: 29110222
Int J Mol Med. 2017 Feb;39(2):453-462
pubmed: 28035360
J Inherit Metab Dis. 2018 Sep;41(5):829-838
pubmed: 29305734
Arch Bronconeumol. 2017 Nov;53(11):657-658
pubmed: 28927944
Neurology. 2006 Jan 24;66(2):228-32
pubmed: 16434659

Auteurs

George A Diaz (GA)

Icahn School of Medicine at Mount Sinai, New York, NY, USA. george.diaz@mssm.edu.

Simon A Jones (SA)

St Mary's Hospital, Manchester University Foundation Trust, University of Manchester, Manchester, UK.

Maurizio Scarpa (M)

Regional Coordinating Center for Rare Diseases, University Hospital Udine, Udine, Italy.

Karl Eugen Mengel (KE)

Clinical Science for LSD, SpinCS, Hochheim, Germany.

Roberto Giugliani (R)

Dept Genetics, UFRGS, Medical Genetics Clinical Research Group, HCPA, and INAGEMP, Porto Alegre, Brazil.

Nathalie Guffon (N)

Reference Center for Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Lyon, France.

Isabela Batsu (I)

Sanofi, Bridgewater, NJ, USA.

Patricia A Fraser (PA)

Sanofi Genzyme, Inc, Cambridge, MA, USA.

Jing Li (J)

Sanofi, Bridgewater, NJ, USA.

Qi Zhang (Q)

Sanofi, Bridgewater, NJ, USA.

Catherine Ortemann-Renon (C)

Sanofi, Bridgewater, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH